Gain Therapeutics advances Parkinson's treatment with GT 2287, showcasing promising safety and tolerability in ongoing trials. Discover the latest findings.
Continuem's PIPE-307 trial for relapsing-remitting multiple sclerosis failed to meet primary goals, yet the company remains committed to exploring future therapies.
Here's some of what is coming soon to NeurologyLive® this week.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on neuromodulation for Parkinson disease!
New findings from the LUMINA trial reveal AMX0114's safety in ALS patients, paving the way for further research and potential treatment advancements.
Neurology News Network for the week ending December 20, 2025. [WATCH TIME: 4 minutes]
GLP-1 research in neurology is on the rise, with several pivotal studies lending insights into their role.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 19, 2025.
Frontlines with Frontera, a podcast hosted by neurointensivist Jennifer Frontera, MD, brings you an exclusive interview with Sahar Zafar, MD, MBBS. [LISTEN TIME: 30 minutes]
The expanded indication brings n-butyl cyanoacrylate’s established performance into the treatment of chronic subdural hematoma, a condition for which traditional surgical interventions may not always be suitable or effective.
Phase 3b study revealed Itvisma's safety and efficacy in treating spinal muscular atrophy, showing modest motor function improvements in patients previously on other therapies.
Angela Lek, PhD, chief research officer of the Muscular Dystrophy Association, discusses the FDA approval of intrathecal onasemnogene abeparvovec (Itvisma; Novartis) and what it means for SMA treatment across older pediatric and adult populations.
At NSGC 2025, the genetic counselor at Johns Hopkins Hospital discussed how cardiac genetics clinics are adopting alternative care models to increase access to genetic testing and counseling. [WATCH TIME: 3 minutes]
Elizabeth Gerard, MD, an epileptologist at Northwestern Medicine, provided clinical insights on a new consortium, GEAN, which aims to expand genetic testing and define adult phenotypes for rare genetic epilepsies across North America.
The director of the Banner Sun Health Research Institute discussed a variety of meaningful Alzheimer disease research presented at the 2024 Clinical Trials on Alzheimer's Disease Conference (CTAD).
A neuroscientist associated with the Cleveland Clinic Epilepsy Center discussed the rapid expansion and excitement surrounding the continued integration of AI in the field of epilepsy care. [WATCH TIME: 5 minutes]
Andy Berkowski, MD, PhD, certified sleep neurologist and author of the RLS guidelines, spoke about the clinical impact of the recently published restless syndrome guidelines.
Walter Kernan, MD, senior research scientist at Yale University, discussed the latest primary stroke prevention guidelines and their focus on lifelong brain health and risk factor management.
The senior vice president of clinical development for Lundbeck provided in-depth commentary on the mechanism of bexicaserin, and the promising early-stage data shown in those with developmental epileptic encephalopathies. [WATCH TIME: 4 minutes]
Christopher Kenney, MD, FAAN, chief medical officer at Xenon Pharmaceuticals, reviews encouraging long-term data behind azetukalner, a first-in-class Kv7 channel opener, as a potential treatment for focal onset seizures.
Neal K. Shah talked about how social robots could support emotional well-being in patients with neurologic conditions by reducing loneliness and promoting engagement in health-related activities.
At AES 2025, a clinical neuropsychologist at the Cleveland Clinic Epilepsy Center discussed the growing challenges facing older adults with epilepsy and the need for more comprehensive, research-informed care strategies. [WATCH TIME: 4 minutes]
Sanofi's tolebrutinib fails to meet key trial endpoints for multiple sclerosis, delaying FDA review and raising questions about its future in treatment.
The professor of translational dementia research at Newcastle University talked about late-breaking data presented at CTAD 2025 on neflamapimod in the phase 2b RewinD-LB trial. [WATCH TIME: 5 minutes]
Here's some of what is coming soon to NeurologyLive® this week.
Andrea Rossetti, MD, director of the EEG/Epilepsy Unit at the Department of Clinical Neurosciences the Lausanne University Hospital in Switzerland, offers insight into post-resuscitation epilepsy care.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on FcRn-blocking therapies in neurology!
Elizabeth Thiele, MD, PhD, director of the Pediatric Epilepsy Program at Massachusetts General Hospital, discusses new data on Epidiolex use in DEEs beyond Dravet, LGS, and TSC.
Neurology News Network for the week ending December 13, 2025. [WATCH TIME: 4 minutes]
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 12, 2025.
